<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321032</url>
  </required_header>
  <id_info>
    <org_study_id>SEC-SUG-2016-01</org_study_id>
    <nct_id>NCT03321032</nct_id>
  </id_info>
  <brief_title>Second-generation Drug-eluting Stents in Diabetes</brief_title>
  <acronym>SUGAR</acronym>
  <official_title>Second-generation drUg-elutinG Stents in diAbetes: a Randomized Trial (the SUGAR Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator initiated randomized trial, performed under the auspices of the
      Spanish Society of Cardiology.

      It is a multicenter, international, parallel, randomized 1:1 (amphilimus-eluting stents vs
      zotarolimus-eluting stents) clinical trial performed exclusively in patients with diabetes
      mellitus. The study has an &quot;all-comers diabetics&quot; design.

      The primary-endpoint is target lesion failure at 1-year follow-up (non-inferiority design)
      and the co-primary end-point is target lesion failure at 2-years follow-up
      (superiority-design).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure at 1-year follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>A composite of cardiac death, any myocardial infarction (not clearly attributable to a non-target vessel), or clinically indicated target-lesion revascularization at 12-months follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion failure at 2-years follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>A composite of cardiac death, any myocardial infarction (not clearly attributable to a non-target vessel), or clinically indicated target-lesion revascularization at 24-months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel myocardial infarction</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Academic Research Consortium definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target lesion revascularization</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1164</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Amphilimus-eluting stents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polymer-free Amphilimus-eluting stents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zotarolimus-eluting stents</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biolinx Polymer-based zotarolimus-eluting stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polymer-free amphilimus-eluting stents</intervention_name>
    <description>Cre8 coronary stent system (CID, Saluggia, Italy)</description>
    <arm_group_label>Amphilimus-eluting stents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biolinx Polymer-based zotarolimus-eluting stents</intervention_name>
    <description>Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)</description>
    <arm_group_label>Zotarolimus-eluting stents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria(must meet all):

          -  Patients ≥18 years who understands the nature of the study and provides written
             informed consent.

          -  Diagnosis of diabetes according to the American Diabetes Association diagnostic
             criteria (*)

          -  Documented silent ischemia, stable angina, unstable angina, or myocardial infarction
             (with or without ST elevation).

          -  At least one de novo coronary lesion with stenosis of more than 50% in a vessel with a
             reference vessel diameter of 2.25 to 4.5 mm by visual estimation. Coronary anatomy is
             suitable for PCI (patients with potential CABG indication should be eligible for PCI
             after a multidisciplinary evaluation in a Heart Team).

        Exclusion Criteria:

          -  Cardiogenic shock or resuscitation

          -  Comorbidity with anticipated life expectancy to 24 months

          -  Inability to consent due to mechanical ventilation

          -  Pregnant female patient

          -  Conditions that could preclude a minimal of 1 month of DAPT (such as, but not limited
             to: severe liver failure, platelet count &lt;100,000 cells/mm3, recent gastrointestinal
             bleeding or history of bleeding diathesis or coagulopathy)

          -  Contraindication or known allergy to aspirin, heparin, P2Y12 inhibitors, cobalt and/or
             chromium metal alloys, sirolimus or derivates, polyurethane, or contrast media (for
             contrast-media allergy, patients that might be safely and adequately pre-medicated
             should be allowed to enter the study).

          -  Currently enrolled in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rafael Romaguera, MD</last_name>
    <phone>+34932607500</phone>
    <email>rafaromaguera@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pablo Salinas, MD</last_name>
    <phone>+34913303283</phone>
    <email>salinas.pablo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Romaguera, MD</last_name>
      <phone>+34932607500</phone>
      <email>rafaromaguera@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Romaguera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Salinas, MD</last_name>
      <phone>913303001</phone>
      <email>salinas.pablo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pablo Salinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Cardiology</investigator_affiliation>
    <investigator_full_name>Dr Rafael Romaguera</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Drug-eluting stents</keyword>
  <keyword>Restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

